Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
CIPLA | PFIZER | CIPLA/ PFIZER |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 31.9 | 43.9 | 72.7% | View Chart |
P/BV | x | 4.5 | 7.3 | 61.9% | View Chart |
Dividend Yield | % | 0.5 | 0.5 | 96.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
PFIZER Mar-19 |
CIPLA/ PFIZER |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 3,840 | 15.2% | |
Low | Rs | 357 | 2,080 | 17.2% | |
Sales per share (Unadj.) | Rs | 207.0 | 455.0 | 45.5% | |
Earnings per share (Unadj.) | Rs | 18.6 | 93.8 | 19.8% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 109.4 | 30.3% | |
Dividends per share (Unadj.) | Rs | 4.00 | 22.50 | 17.8% | |
Dividend yield (eoy) | % | 0.8 | 0.8 | 111.7% | |
Book value per share (Unadj.) | Rs | 195.5 | 658.2 | 29.7% | |
Shares outstanding (eoy) | m | 806.35 | 45.75 | 1,762.5% | |
Bonus/Rights/Conversions | ESOS | - | - | ||
Price / Sales ratio | x | 2.3 | 6.5 | 35.0% | |
Avg P/E ratio | x | 25.3 | 31.6 | 80.3% | |
P/CF ratio (eoy) | x | 14.2 | 27.1 | 52.5% | |
Price / Book Value ratio | x | 2.4 | 4.5 | 53.6% | |
Dividend payout | % | 21.5 | 24.0 | 89.7% | |
Avg Mkt Cap | Rs m | 379,912 | 135,420 | 280.5% | |
No. of employees | `000 | 25.8 | 2.6 | 982.3% | |
Total wages/salary | Rs m | 30,270 | 3,238 | 934.7% | |
Avg. sales/employee | Rs Th | 6,459.6 | 7,911.4 | 81.6% | |
Avg. wages/employee | Rs Th | 1,171.2 | 1,230.9 | 95.2% | |
Avg. net profit/employee | Rs Th | 580.2 | 1,630.7 | 35.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 20,815 | 802.1% | |
Other income | Rs m | 3,442 | 1,674 | 205.6% | |
Total revenues | Rs m | 170,391 | 22,489 | 757.7% | |
Gross profit | Rs m | 32,060 | 5,712 | 561.3% | |
Depreciation | Rs m | 11,747 | 714 | 1,645.4% | |
Interest | Rs m | 1,974 | 73 | 2,707.3% | |
Profit before tax | Rs m | 21,782 | 6,599 | 330.1% | |
Minority Interest | Rs m | -475 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,312 | 2,309 | 273.4% | |
Profit after tax | Rs m | 14,995 | 4,291 | 349.5% | |
Gross profit margin | % | 19.2 | 27.4 | 70.0% | |
Effective tax rate | % | 29.0 | 35.0 | 82.8% | |
Net profit margin | % | 9.0 | 20.6 | 43.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 27,167 | 430.8% | |
Current liabilities | Rs m | 43,931 | 8,917 | 492.7% | |
Net working cap to sales | % | 43.8 | 87.7 | 49.9% | |
Current ratio | x | 2.7 | 3.0 | 87.4% | |
Inventory Days | Days | 96 | 68 | 141.2% | |
Debtors Days | Days | 85 | 30 | 282.6% | |
Net fixed assets | Rs m | 107,424 | 8,862 | 1,212.2% | |
Share capital | Rs m | 1,613 | 458 | 352.5% | |
"Free" reserves | Rs m | 156,018 | 29,656 | 526.1% | |
Net worth | Rs m | 157,630 | 30,113 | 523.5% | |
Long term debt | Rs m | 23,693 | 25 | 94,771.2% | |
Total assets | Rs m | 236,626 | 39,400 | 600.6% | |
Interest coverage | x | 12.0 | 91.5 | 13.2% | |
Debt to equity ratio | x | 0.2 | 0 | 18,104.9% | |
Sales to assets ratio | x | 0.7 | 0.5 | 133.5% | |
Return on assets | % | 7.2 | 11.1 | 64.8% | |
Return on equity | % | 9.5 | 14.2 | 66.8% | |
Return on capital | % | 12.8 | 22.1 | 58.0% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 428 | 13,083.4% | |
Fx outflow | Rs m | 6,764 | 786 | 860.1% | |
Net fx | Rs m | 49,272 | -358 | -13,759.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 978 | 3,137.2% | |
From Investments | Rs m | 1,040 | 351 | 296.2% | |
From Financial Activity | Rs m | -29,488 | -1,099 | 2,684.4% | |
Net Cashflow | Rs m | 2,340 | 231 | 1,014.0% |
Indian Promoters | % | 16.0 | 0.0 | - | |
Foreign collaborators | % | 20.8 | 63.9 | 32.6% | |
Indian inst/Mut Fund | % | 12.2 | 7.5 | 162.7% | |
FIIs | % | 23.7 | 4.9 | 483.7% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 23.7 | 110.5% | |
Shareholders | 161,166 | 85,207 | 189.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: STERLING BIOTECH NOVARTIS ALEMBIC PHARMA SHASUN PHARMA SANOFI INDIA
Compare CIPLA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More